Andrzej Czernikiewicz

Andrzej Czernikiewicz

Auto-generated profile, based on publicly available information

Andrzej Czernikiewicz

Department of Speech Therapy and Applied Linguistics , Maria Curie Skłodowska University , Lublin , Poland

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2005 in Pharmacopsychiatry
Verified
Journal Article
Closed access
ASAgata Szulc
Agata Szulc
BGBeata Galińska-Skok
Beata Galińska-Skok
ETE. Tarasow
E. Tarasow
WDW. Dzienis
W. Dzienis
BKB. Kubas
B. Kubas
ACA. Czernikiewicz
A. Czernikiewicz
Objective: The aim of the study was the evaluation of risperidone effect on metabolite measures in the frontal lobe, temporal lobe and thalamus in schizophrenic patients on the basis of proton magnetic resonance spectroscopy (1H MRS). Methods: A group of 14 patients with the diagnosis of schizophrenia, according to DSM-IV, were examined in the study. The patients were examined twice, once after a period of at least 7 days without neuroleptics and for the second time at least 4 weeks after stable risperidone doses. Results: The significant differences in the metabolite levels before and after the treatment were observed only in thalamus: an increase in myoinositol (mI) and N-acetylaspartate (NAA) levels. Positive symptoms before the treatment correlated positively with NAA level in the frontal lobes and negatively in the temporal lobes. Negative symptoms before the treatment correlated positively with Glx (a common signal for GABA, glutamine and glutamate) level in the temporal lobes. Conclusion: Our results seem to confirm the influence of risperidone on the brain metabolism, specifically in the region of thalamus.

30 January 2008 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
Napoleon WaszkiewiczNapoleon Waszkiewicz
Napoleon Waszkiewicz
SSSławomir Dariusz Szajda
Sławomir Dariusz Szajda
AJAnna Jankowska
Anna Jankowska
PZPiotr Zwierz
Piotr Zwierz
ACAndrzej Czernikiewicz
Andrzej Czernikiewicz
KZKrzysztof Zwierz
Krzysztof Zwierz

25 December 2014 in Psychiatria Polska
Verified
Journal Article
Open access
MJMarek Jarema
Marek Jarema
DDDominika Dudek
Dominika Dudek
ACAndrzej Czernikiewicz
Andrzej Czernikiewicz
Zaburzenia funkcji poznawczych są integralną częścią obrazu klinicznego depresji, ale nie poświęca się im zasadniczej uwagi, głównie z powodu przekonania, że są one wtórne wobec innych, typowych objawów depresji. Uważa się, że dysfunkcje poznawcze stanowią jedną z przyczyn złego funkcjonowania chorych na depresję. Deficyty poznawcze są obecne już w pierwszym epizodzie depresji. Uważa się, że są one związane z nasileniem objawów depresji, hospitalizacją, wiekiem i wykształceniem chorych na depresję. Mogą się utrzymywać pomimo istotnej poprawy w zakresie innych objawów depresyjnych. Deficyty poznawcze w depresji dzielą się na „zimne” (niezwiązane z emocjami) i „gorące” (związanym z emocjami). Te deficyty kognitywne związane z poznaniem zimnym wydają się nie ustępować w czasie remisji, a przetrwałe deficyty tego typu wiążą się z gorszą reakcją na leki przeciwdepresyjne. Wortioksetyna to nowy lek przeciwdepresyjny o unikalnych mechanizmie działania: wpływa nie tylko na transport zwrotny serotoniny, ale wykazuje działanie agonistyczne wobec receptorów serotoninowych 5-HT 1A, będąc częściowym agonistą receptorów 5-HT 1B lub antagonistą receptorów 5-HT 1D , 5-HT 3 i 5-HT 7. W badaniach przedklinicznych, wortioksetyna znacząco normalizowała neurotransmisję serotoninergiczną, noradrenergiczną i dopaminergiczną, a dodatkowo przez efekt GABAergiczny i glutaminianergiczny. Działa przeciwdepresyjnie, jest skuteczna w różnych postaciach depresji: ciężkiej, z lękiem, u osób starszych; okazała się skuteczna u chorych, którzy nie odpowiadają wystarczająco na leczenie lekami z grupy SSR lub SNRI. Wpływakorzystnienafunkcjepoznawcze u chorychnadepresję.

1 April 2012 in Clinical Schizophrenia & Related Psychoses
Verified
Journal Article
Closed access
KKKatarzyna Kucharska-Pietura
Katarzyna Kucharska-Pietura
AMAnn Mortimer
Ann Mortimer
ATAneta Tylec
Aneta Tylec
ACAndrzej Czernikiewicz
Andrzej Czernikiewicz
Social cognition captures affect recognition, social cue perception, "theory of mind," empathy, and attributional style. The aim of our study was to assess social cognition in schizophrenia inpatients being treated with first-generation antipsychotic drugs (FGAs), n=28 (perphenazine and haloperidol, FGAs) or with second-generation antipsychotic drugs (SGAs), n=56 (olanzapine and clozapine, SGAs). Eighty-four patients completed the Facial Expression Recognition Test, the Voice Emotion Recognition Test, the Short Recognition Memory Test for Faces, and the Reading the Mind in the Eyes Test. Patients also completed the Visual Object and Space Perception Test (VOSP) as a control task, which would not engage social cognition. The patients were compared with fifty healthy controls matched for age and gender. There were no significant differences on social cognitive performance between the FGA- and SGA-treatment groups. Nor was olanzapine superior to clozapine, FGAs or both. However, patients treated with FGAs performed significantly worse on VOSP compared to both groups treated with SGAs, a 10% difference. We cannot conclude that SGAs were associated with better social cognition than FGAs. However, there were small but significant advantages for SGAs in non-social visual processing function, as evaluated with the VOSP.

1 January 2012 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
KKKatarzyna Kucharska-Pietura
Katarzyna Kucharska-Pietura
ATAneta Tylec
Aneta Tylec
ACAndrzej Czernikiewicz
Andrzej Czernikiewicz
AMAnn Mortimer
Ann Mortimer
Effectiveness of antipsychotics in treating emotional and cognitive deficits in schizophrenia still remains controversial. The aim of our study was to assess emotional and cognitive functioning in schizophrenic inpatients currently treated with typical antipsychotics (perphenazine, perazine, fluphenazine, and haloperidol) and in another group of schizophrenic inpatients currently on atypical antipsychotics (olanzapine, risperidone, amisulpride, and quetiapine). One hundred patients with DSM-IV schizophrenia or schizoaffective disorders (39 treated using typical antipsychotics and 61 treated with atypical antipsychotics) under naturalistic treatment conditions, and 50 healthy controls were given the following: Test of Everyday Attention, Facial Emotion Recognition Test, Facial Memory Recognition Test, and “Reading the mind in the eyes” Test. Patients with a diagnosis of schizophrenia revealed the following deficits: facial emotion perception, empathy/theory of mind, visual selective attention/speed, attentional switching, and auditory-verbal working memory. Our results show a significant difference between schizophrenic and healthy controls in all tasks, with schizophrenic patients performing worse than controls. Interestingly, our patients on atypical neuroleptics performed similarly compared to schizophrenic patients treated with conventional neuroleptics on all tasks provided. There were some significant relationships between emotional and cognitive deficits and clinical variables. Our findings remain consistent with other recent studies in which atypical antipsychotics did not show a clear advantage over typical antipsychotics on both emotional and cognitive functioning.

1 May 2007
Verified
Journal Article
Closed access
ASAgata Szulc
Agata Szulc
BGBeata Galińska
Beata Galińska
ETEugeniusz Tarasów
Eugeniusz Tarasów
BKBozena Kubas
Bozena Kubas
WDWojciech Dzienis
Wojciech Dzienis
JWJerzy Walecki
Jerzy Walecki